Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine

被引:81
作者
Schroeder, JT
Schleimer, RP
Lichtenstein, LM
Kreutner, W
机构
[1] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Unit Off 2,Dept Med,Div Clin Immunol, Baltimore, MD 21224 USA
[2] Schering Plough Res Inst, Kenilworth, NJ USA
关键词
H-1-receptor; antagonist; cytokine; IgE; basophil; leukotriene; histamine;
D O I
10.1046/j.1365-2222.2001.01130.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background Desloratadine, is a non-sedating, clinically effective, anti-allergic therapy that has been shown to exhibit anti-inflammatory properties that extend beyond its ability to antagonize histamine at H-1-receptor sites. This latter effect has been shown in vitro to be both IgE-dependent and -independent. Objective In this study, we addressed the ability of desloratadine to inhibit the in vitro generation of interleukin (IL)-4 and IL-13 from human basophils while concurrently comparing its efficacy in preventing mediator release by these cells. Methods Basophil-enriched suspensions were treated with various concentrations of desloratadine for 15 min before stimulating with either anti-IgE antibody, calcium ionophore, IL-3 or phorbol ester. Histamine (fluorimetry), LTC4 (RIA) and IL-4 (ELISA) were all assayed using the same 4-h culture supernatants. IL-13 (ELISA) was measured in supernatants harvested after 20 h incubation. IL-4 mRNA expression (dilutional RT-PCR) was also examined. Results Desloratadine was found to be nearly six-seven times more potent in preventing the secretion of IL-4 and IL-13 induced by anti-IgE than it was at inhibiting the release of histamine and LTC4. These cytokines were equally inhibited by desloratadine following activation with ionomycin despite the lack of an effect on the histamine induced with ionomycin. Desloratadine had a lesser effect regarding inhibition of the IL-13 secreted in response to IL-3 and PMA. There was no evidence that desloratadine mediated its inhibitory effects by causing decreased cell viability. Finally, IL-4 mRNA accumulation was remarkably inhibited, by as much as 80%, following pretreatment with desloratadine. Conclusion While capable of inhibiting histamine and LTC4 release by human basophils, desloratadine is more effective at targeting the signals regulating IL-4 and IL-13 generation in these cells. This inhibitory effect on cytokine generation provides additional evidence that this antihistamine exerts anti-inflammatory properties.
引用
收藏
页码:1369 / 1377
页数:9
相关论文
共 26 条
[1]  
Albanesi C, 1998, CLIN EXP ALLERGY, V28, P101
[2]  
Atamas SP, 1996, J IMMUNOL, V156, P435
[3]   IN-VITRO INHIBITION, BY LORATADINE AND DESCARBOXYETHOXYLORATADINE, OF HISTAMINE-RELEASE FROM HUMAN BASOPHILS, AND OF HISTAMINE-RELEASE AND INTRACELLULAR CALCIUM FLUXES IN RAT BASOPHILIC LEUKEMIA-CELLS (RBL-2H3) [J].
BERTHON, B ;
TAUDOU, G ;
COMBETTES, L ;
CZARLEWSKI, W ;
CARMILEROY, A ;
MARCHAND, F ;
WEYER, A .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (05) :789-794
[4]  
CHURCH MK, 1980, BRIT J PHARMACOL, V9, P663
[5]  
Ciprandi G, 1997, J ALLERGY CLIN IMMUN, V100, P146
[6]  
EDA R, 1994, ANN ALLERGY, V73, P154
[7]   Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells [J].
Genovese, A ;
Patella, V ;
DeCrescenzo, G ;
DePaulis, A ;
Spadaro, G ;
Marone, G .
CLINICAL AND EXPERIMENTAL ALLERGY, 1997, 27 (05) :559-567
[8]   Inhibition of interleukin-4 and interleukin-13 release from immunologically activated human basophils due to the actions of anti-allergic drugs [J].
Gibbs, BF ;
Vollrath, IB ;
Albrecht, C ;
Amon, U ;
Wolff, HH .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (05) :573-578
[9]  
GILBERT HS, 1975, BLOOD, V46, P279
[10]   INHIBITION OF IGE-MEDIATED AND NON-IGE-MEDIATED HISTAMINE-RELEASE FROM HUMAN BASOPHIL LEUKOCYTES IN-VITRO BY A HISTAMINE H-1-ANTAGONIST, DESETHOXYCARBONYL-LORATADINE [J].
KLEINETEBBE, J ;
JOSTIES, C ;
FRANK, G ;
STALLEICKEN, D ;
BUSCHAUER, A ;
SCHUNACK, W ;
KUNKEL, G ;
CZARNETZKI, B .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 93 (02) :494-500